Nkarta Inc (NKTX NASDAQ) stock market data APIs
$1.9758
0.06(3%)
as of September 12, 2025
Try our APIs with
free plan!
Nkarta Inc Financial Data Overview
Price chart is built with
Anychart
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Prev. Close
1.9758
Open
2.0371
High
2.0371
Low
1.9574
52 wk Range
1.31-5.829
Market Cap
140 M
Shares Outstanding
71 024 K
Revenue
385
EPS
-0.31
Beta
0.767
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nkarta Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nkarta Inc data using free add-ons & libraries
Get Nkarta Inc Fundamental Data
Nkarta Inc Fundamental data includes:
- Net Revenue: 385
- EBITDA: -114 102 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nkarta Inc News
New
Nkarta to Participate in a September Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, toda...
Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today...
Nkarta CMO David Shook Steps Down, Shawn Rose To Succeed
(RTTNews) - Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, on Friday announced that Chief Medical Officer David Shook will be stepping down and Shawn Rose will take over as CMO and H...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
